Kinaxo Lands New Investors, Funding for Biomarker Development | GenomeWeb

NEW YORK (GenomeWeb News) – Germany's Kinaxo Biotechnologies said today that it has brought on two new investors and closed a financing round worth an undisclosed amount.

Kinaxo, based in Martinsried, said it will use the funding to develop novel biomarkers that allow stratification of cancer patients receiving targeted therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.